Graft-versus-leukemia: no longer an epiphenomenon.
暂无分享,去创建一个
[1] H. Sagara,et al. Transfusion-associated graft-versus-host disease. , 1993, Fukushima journal of medical science.
[2] M. Horowitz,et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose , 1993 .
[3] B. Chapuis,et al. Adoptive immunotherapy for recurrent CML after BMT. , 1993, Bone marrow transplantation.
[4] P. Quesenberry,et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. , 1993, Blood.
[5] R. Truitt,et al. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. , 1993, Bone marrow transplantation.
[6] T. Smetsers,et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Szer,et al. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. , 1993, Bone marrow transplantation.
[8] W. Wilmanns,et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. , 1993, Transplantation proceedings.
[9] J. Radich,et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Barrett,et al. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. , 1993, Bone marrow transplantation.
[11] J. Ferrara,et al. Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.
[12] R. Collins,et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. , 1992, Bone marrow transplantation.
[13] J. Ritz,et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. , 1992, Blood.
[14] A. Feinberg,et al. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. , 1991, The Journal of clinical investigation.
[15] A. Rimm,et al. T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.
[16] P. Martin. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. , 1991, Bone marrow transplantation.
[17] L. Verdonck,et al. Amplification of the graft-versus-leukemia effect in man by interleukin-2. , 1991, Transplantation.
[18] S. Piantadosi,et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. , 1991, Blood.
[19] S. Mackinnon,et al. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. , 1990, Blood.
[20] C. Perreault,et al. Minor histocompatibility antigens. , 1990, Blood.
[21] S. Feig,et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.
[22] K. Sullivan,et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. , 1990, Transplantation.
[23] L. Barnett,et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.
[24] S. Smith,et al. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. , 1990, Blood.
[25] K. Offit,et al. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. , 1990, Blood.
[26] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[27] H. Heslop,et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.
[28] K. Sullivan,et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.
[29] W. Gregory,et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect , 1988, British journal of haematology.
[30] R. Hoffmann,et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .
[31] J. Hank,et al. Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial , 1985, Cancer.
[32] R. Gale,et al. HOW DOES BONE-MARROW TRANSPLANTATION CURE LEUKAEMIA? , 1984, The Lancet.
[33] K. Sullivan,et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.
[34] K. Sullivan,et al. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. , 1981, Transplantation proceedings.
[35] G. Mathé,et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.
[36] M. Tubiana,et al. SUCCESSFUL ALLOGENIC BONE MARROW TRANSPLANTATION IN MAN: CHIMERISM, INDUCED SPECIFIC TOLERANCE AND POSSIBLE ANTI-LEUKEMIC EFFECTS. , 1965, Blood.
[37] J. Loutit,et al. Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.
[38] J. Loutit,et al. Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.
[39] A. Nagler,et al. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. , 1992, Cancer investigation.
[40] M. Horowitz,et al. Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.
[41] D. Ginsburg,et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992, Blood.
[42] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.
[43] D. Peakman,et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? , 1978, Lancet.